Mohit Trikha, Ph.D.

Vice President, Head of Oncology Early Development, AbbVie

Dr. Trikha is the vice president and head of Oncology Early Development at AbbVie and responsible for advancing the oncology pipeline from candidate selection through clinical proof of concept. At AbbVie, he chairs the Early Development Advisory Council and is a member of multiple cross functional committees.  He is a core member of AbbVie’s Oncology Licensing Committee and chairs multiple external collaborations. Dr. Trikha is also the Bay Area Site Head, responsible for defining and driving the mission and vision for AbbVie in the Bay Area and our future home in South San Francisco. Prior to AbbVie he was President and Chief Scientific Officer, Head of Triphase Accelerator, Board member of Triphase and EnCycle Therapeutics. Over his 20 years of oncology drug discovery and development experience, Dr. Trikha helped discover three now approved cancer medicines and contributed to advancing more than twenty oncology programs to clinical proof of concept while he was at Centocor/Johnson & Johnson, Genentech, Ambit, and Triphase Accelerator. Dr. Trikha continues to focus his science interests in advancing first or best in class oncology medicines, cell signaling, tumor immunology, apoptosis, protein homeostasis, CMC, PKPD, and biomarkers for predicting clinical response and toxicity.  He received his B.S. from California State University, Los Angeles, and his Ph.D. from University of Southern California and was an Assistant Professor of Research at Wayne State University prior to joining industry.